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Introduction
The use of biological DMARDs have significantly
improved the prognosis and prospects for patients with
juvenile idiopathic arthritis (JIA). Today the main problem
for pediatric rheumatologists when choosing JIA treatment
is the absence of comparative controlled studies of efficacy
and safety of different biological DMARD.
Objectives
To compare efficacy and safety of etanercept and abata-
cept in pediatric patients with polyarticular JIA.
Methods
The study enrolled 54 pediatric patients with polyarticular
JIA, 32 of them received etanercept and 22 received abata-
cept. The demographic parameters were well matched
across treatment groups. The mean age of children was
10.8 ± 3.7, the age at the disease onset was 5.4 ± 3.4, most
of the patients were female. Prior to biological DMARD
administration, all the subjects received multiple basic
immunosuppressants. A total of 68,7 % of subjects in the
etanercept arm had disease activity grade II before biologi-
cal DMARD administration, 31.3% had grade III; 54.6% of
subjects in the abatacept arm had disease activity grade I,
31.8% grade II, and 13.6% grade III. American College of
Rheumatology “pediatric” criteria (ACR pedi-30, -50, -70,
-90), treatment compliance index and index LUNDEX
were used to assess efficacy of the study treatment. Biolo-
gical DMARD efficacy and safety were evaluated at
Months 6, 12, 18 and 24 following therapy initiation. The
drugs were given at standard doses.
Results
At least a 50% improvement according to ACR pedi was
achieved in 84.3% of etanercept arm subjects and in 71,4%
in patients receiving abatacept following 6 months of
treatment. Drug-induced clinical and laboratory remission
(ACR pedi 90,100) was achieved in 15.6% of subjects in
the etanercept arm, and in 9.5% of patients receiving aba-
tacept. After that, biological DMARD efficacy continued
to increase. At Month 18, ACR pedi 50 was achieved in
100% and ACR pedi 90 in 31.0% of etanercept subjects;
ACR pedi 50 was achieved in 83,3%, and ACR pedi 90 in
33.3% of abatacept subjects. The treatment compliance
index at Month 18 was 0,97 in the etanercept arm and 0.8
in the abatacept arm. Index LUNDEX was 0.97 for ACR
pedi 50, and 0,3 for ACR pedi 90 in the etanercept arm; in
the abatacept arm, it was 0.67 for ACR pedi 50, and 0.27
for ACR pedi 90. At Month 24 all the patients achieved a
50% response according to the ACR pedi criteria. Drug-
induced clinical and laboratory remission was achieved in
43.0% of subjects in the etanercept arm, and in 67% of
subjects in the abatacept arm. A greater treatment compli-
ance index was obtained in the etanercept arm (0.94
versus 0.6 in the abatacept arm). Thus, when biological
DMARD efficacy is compared using index LUNDEX to
ACR pedi 50, the best result was obtained with etanercept
when compared to abatacept, the values were 0,94 and 0,6,
respectively. Index LUNDEX to ACR pedi 90, 100 was 0,4
in both arms. The difference between biological DMARD
efficacy was not significant (p<0,05). Adverse drug reac-
tions were more frequent in the abatacept arm (22.7%)
than in the etanercept arm (12.5%). Serious adverse reac-
tions were also more frequent with abatacept treatment
(9%) than with etanercept (3%; p>0.05).
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Conclusion
Etanercept and abatacept are highly effective drugs for
pediatric treatment of polyarticular JIA. Etanercept has a
better safety profile than abatacept.
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